XML 54 R44.htm IDEA: XBRL DOCUMENT v3.19.1
Collaborative Arrangements and Licensing Agreements, Novartis (Details) - USD ($)
$ in Thousands, shares in Millions
3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Dec. 31, 2018
Collaborative Arrangement and Licensing Agreement [Abstract]      
Revenue $ 297,214 $ 144,419  
R&D [Member]      
Collaborative Arrangement and Licensing Agreement [Abstract]      
Revenue 229,126 $ 102,396  
Novartis [Member]      
Collaborative Arrangement and Licensing Agreement [Abstract]      
Deferred revenue $ 23,300   $ 28,800
Novartis [Member] | Revenue [Member] | Strategic Partner [Member]      
Collaborative Arrangement and Licensing Agreement [Abstract]      
Concentration percentage 53.00% 12.00%  
Novartis [Member] | Minimum [Member]      
Collaborative Arrangement and Licensing Agreement [Abstract]      
Cumulative payments received $ 330,000    
Novartis [Member] | AKCEA-APO(a)-L [Member]      
Collaborative Arrangement and Licensing Agreement [Abstract]      
Revenue 150,000    
Novartis [Member] | R&D [Member]      
Collaborative Arrangement and Licensing Agreement [Abstract]      
Revenue 157,100 $ 17,100  
Akcea [Member]      
Collaborative Arrangement and Licensing Agreement [Abstract]      
Sublicense fee paid in stock $ 75,000    
Additional shares of Akcea stock received (in shares) 2.8